Combined pharmaceutical composition of pyrrolo[2,3-c]pyridone compound and use thereof

HK40137381APending Publication Date: 2026-09-11CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124877
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2026-06-16
Publication Date
2026-09-11
Patent Text Reader

Abstract

The invention relates to a combined pharmaceutical composition of pyrrolo [2, 3-c] pyridone compounds and application of the combined pharmaceutical composition. Specifically, the invention relates to a combined pharmaceutical composition of a compound shown as a formula (I) and application of the combined pharmaceutical composition to treatment of myelofibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480027334.X (22) Application Date 2024.05.08 (66) Domestic Priority Data 202310518474.4 2023.05.09 CN (85) PCT International Application Entering National Phase Date 2025.10.22 (86) PCT International Application Application Data PCT / CN2024 / 091682 2024.05.08 (87) PCT International Application Publication Data WO2024 / 230727 ZH 2024.11.14 (71) Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address: 369 Yuzhou South Road, Lianyungang City, Jiangsu Province, 222062, China Inventor No. (72) Inventors: Ding Dawei, Yu Ding, Wang Xunqiang, Zhang Xiquan, Zhao Wei, Lao Shanli (51) Int.Cl. C07D 471 / 04 (2006.01) A61P 35 / 00 (2006.01) A61K 31 / 437 (2006.01) A61K 31 / 519 (2006.01) C07D 487 / 04 (2006.01) (54) Invention Title: A combination pharmaceutical composition of pyrrolo[2,3-c]pyridinone compounds and its use therein (57) Abstract: A combination pharmaceutical composition relating to pyrrolo[2,3-c]pyridinone compounds and its use therein. Specifically, it relates to a combination pharmaceutical composition of compounds of formula (I) and its use in the treatment of myelofibrosis. CN 121285550 A 2026.01.06 CN 1 21 28 55 50 A